Novo Nordisk’s Wegovy will be competing with Madrigal Pharmaceuticals’ Rezdiffra in the metabolic dysfunction-associated ...

Nobuyuki Ishibashi, MD, professor of anatomy & neurobiology at Boston University Chobanian & Avedisian School of Medicine, has been awarded a four-year, $6.5 M grant from the Department of Defense’s ...

The published data provide evidence that inflammasome-induced inflammation plays a central role in the development and progression of T2DM and its cardiovascular complications by promoting insulin ...

ZyVersa Therapeutics (ZVSA) highlights data from a peer-reviewed article, The Role of NLRP3 Inflammasome in Type 2 Diabetes Mellitus and Its ...

The FDA approved oral rilzabrutinib (Wayrilz) for treating persistent or chronic immune thrombocytopenia (ITP), the agency announced on Tuesday. As the first Bruton's tyrosine kinase (BTK) inhibitor ...

The FDA has approved rilzabrutinib (Wayrilz; Sanofi) as a groundbreaking treatment for immune thrombocytopenia (ITP), enhancing patient outcomes and quality of life. ITP is characterized by platelet ...

Two nonrandomized, open-label phase II subprotocols within the context of the NCI-MATCH trial targeted PTEN tumor alterations in patients with advanced relapsed/refractory solid tumors, lymphoma, or ...

After throwing down $70 million upfront to partner on Black Diamond Therapeutics’ solid tumor candidate earlier this year, Servier is pulling out its checkbook to ink yet another oncology licensing ...

Fosun Pharma has penned its third inflammatory disease pact in three weeks, plucking up China rights to a clinical-stage treatment from Accro Bioscience. Shanghai-based Fosun is putting down 60 ...

Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials RAHWAY, N.J.--(BUSINESS WIRE)- ...